Molecular diagnostics company CareDx nets $7.8mm in FOPO

15:40 EDT 21 Sep 2016 | Elsevier Business Intelligence

CareDx Inc. (molecular diagnostics for transplant patients) netted $8.4mm in a follow-on public offering of 2.25mm common shares at $4. Earlier in the year the company raised additional funds in a private placement to support its acquisition of Allenex AB. The company will use the proceeds to support the continued development of AlloSure for a clinical utility trial and commercialization.

Original Article: Molecular diagnostics company CareDx nets $7.8mm in FOPO


More From BioPortfolio on "Molecular diagnostics company CareDx nets $7.8mm in FOPO"

Quick Search

Relevant Topics

A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease to confirm that a person is free from disease Clin...

Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...